Small Molecules
3 October 2017
FDA Accepts Supplemental New Drug Application (sNDA) filing for AVYCAZ® (ceftazidime and avibactam)3 October 2017
Esperion Completes Patient Enrollment in Global Pivotal Phase 3 Program for Bempedoic Acid30 September 2017
Radius Health Initiates Phase 1 Clinical Trial of RAD140 for the Treatment of Hormone Receptor Positive Breast Cancer30 September 2017
INSYS Therapeutics Files New Drug Application (NDA) for Buprenorphine Sublingual Spray with FDA30 September 2017
Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome30 September 2017
Merck Discontinues MK-3682B and MK-3682C Development Programs28 September 2017
Eidos Therapeutics Initiates First Clinical Study for AG10 Targeting Transthyretin Amyloidosis, Appoints Camille Landis as Chief Business Officer28 September 2017
Tricida Initiates Phase 3 Study of TRC101 for the Treatment of Metabolic Acidosis Associated With Chronic Kidney Disease28 September 2017
Zynerba Pharmaceuticals Announces Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile X Syndrome28 September 2017
Savara Announces Start of Pivotal Phase III AVAIL Study of AeroVanc27 September 2017
Mateon Therapeutics Announces Termination of FOCUS Study in Ovarian Cancer and Restructuring to Prioritize OXi4503 for AML27 September 2017
Aduro Biotech Announces Advancement of ADU-S100 into Global Combination Trial With PDR001 for the Treatment of Solid Tumors and Lymphomas27 September 2017
Intellia Therapeutics Demonstrates Sustained and Durable Genome Editing with CRISPR/Cas9 in One-Year Animal Study27 September 2017
Axovant Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimer’s Disease26 September 2017
European Commission Approves Symtuza® for the Treatment of HIV-1 In Adults and Adolescents in Europe26 September 2017
Medivir Announces Positive Topline Results from Phase IIa Osteoarthritis Study, Showing Disease-modifying Benefit of MIV-711 on Joint Structure26 September 2017
Gelesis100 Achieves Significant Weight Loss with Excellent Safety Profile in Pivotal Study25 September 2017
Janssen Submits New Drug Application to U.S. Food and Drug Administration for the First Darunavir-Based Single Tablet Regimen for the Treatment of HIV-125 September 2017
NewLink Genetics Announces Clinical Collaboration to Evaluate IO-Based Combination Therapies in Pancreatic Cancer25 September 2017
Athenex, Inc. Announces First Patient Recruitment in Phase III Clinical Trials for KX-01 Ointment for Actinic Keratosis25 September 2017
Acer Therapeutics Reports Positive Results From Pivotal Clinical Trial of EDSIVO™ (celiprolol) for Treatment of Vascular Ehlers-Danlos Syndrome25 September 2017
Prometic receives FDA clearance of its IND to initiate pivotal PBI-4050 Phase 2/3 trial in patients with idiopathic pulmonary fibrosis25 September 2017
AMO Pharma Reports Update on Positive Interim Analysis for the First Cohort of Phase IIa Congenital Myotonic Dystrophy StudyNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports